CreditAccess Grameen’s (CREDAG) Q4FY24 earnings were ahead of estimates, driven by steady NIMs (13.1%) and healthy loan growth (+27% YoY)...

We upgrade GCPL to BUY from ADD with a TP of Rs 1450 (50x FY26 EPS, 20% premium to its 5-year average PE) as it is poised to deliver reve...

Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, Ind...

Kotak Mahindra Bank (KMB) has underperformed the Bank Nifty by ~20% over the past few months on the back of three key developments: CEO t...

We believe Britannia’s biscuits portfolio can deliver mid to high single-digit volume growth (6% volume CAGR over FY14-24) in the medium...

We upgrade Marico to BUY from ADD with TP of Rs 650 (45x FY26 EPS, 10% premium to its 5 year Average PE) and move it to high conviction l...

Mahindra & Mahindra Financial Services: MMFS reported yet another quarter of earnings de-growth (-10% YoY) due to higher-than-expected pr...

Titan: Jewellery (ex-bullion) sales grew 21.8% YoY to INR98.24bn (HSIE: 105.62bn). Domestic standalone jewellery sales (ex-bullion) grew ...

Cholamandalam Investment and Finance Company: Chola’s Q4FY24 earnings were ahead of our estimates on account of strong AUM growth (+37% Y...

Ambuja Cement: We maintain ADD with an unchanged TP of INR 620/share (16.5x its consolidated FY26E EBITDA). During Q4FY24, consolidated v...

Subscribe for our
newsletter

Reports

__heading__